- Hyderabad-based fast growing Pharmaceutical company having
a wide presence in the export market (almost 95% of the turnover of the company is from
exports).
- Good research facilities, which have been recognized as
R&D Centers by the Department of Scientific and Industrial Research (DSIR) of the
Government of India
- Recognized as a "Trading House" by the Director
General of Foreign Trade, Ministry of Commerce, Government of India. It also has been
awarded ISO 9001 and ISO 9002 Certification from SGS Yarsley International Certification
Services Limited, U.K.
- Certification for being in compliance with World Health
Organization – Good Manufacturing Practices (WHO-GMP). It also had obtained the
Certificate of Suitability for Naproxen from European Directorate, Germany for the quality
of Medicines
- Filed its Drug Master Files for 4 products with the US FDA
and for 2 products with the European Directorate, Germany for obtaining their approvals.
(Compliance with these regulations will enable Divi’s to sell products in the
advanced markets)
- Promoted by a technocrat, Mr. Murali K. Divi, who has more
than 25 years of experience in the Active Pharmaceutical Ingredients (API) Industry.
Projected required working capital for the year 2000-01
stands at Rs. 438.9 lakhs.
- NRIs can apply on NRE/FCNR accounts and on repatriation
basis.
Total income increased from Rs.54.36 crore in 1996 to
nearly Rs.100.59 crore in FY99. The half year closed on Sept 1999 with a total revenue of
Rs. 75.31 crore. During the same period, the net profit decreased from Rs.8.24 crore to
Rs.6.50 crore, however, in the half year it increased to Rs. 7.29 crore.
|
